Please note, this OEL/ADE monograph also applies to netarsudil mesylate (CAS RN 1422144-42-0). Netarsudil is a Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Netarsudil is a rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous humor. The exact mechanism of netarsudil is unknown. It is suggested that netarsudil possess inhibitory action against the norepinephrine transporter, preventing reuptake of norepinephrine at noradrenergic synapses and increasing the strength and duration of norepinephrine signaling. Norepinephrine-induced vasoconstriction reducing blood flow to the ciliary body may subsequently be responsible for the reduction of aqueous humor.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL/ADE monograph for Netarsudil, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.